Hyperphosphatemia and Chronic Kidney Disease Nexus
Bacchetta, J., Bernardor, J., Garnier, C., Naud, C., & Ranchin, B. (2021). Hyperphosphatemia and chronic kidney disease: A major daily concern both in adults and in children. Calcified Tissue International, 108(18), 116-127.
The method of the study was the analysis of the pathophysiology of hyperphosphatemia in chronic kidney disease. The study’s design was to describe the negative impact of hyperphosphatemia in chronic kidney disease and then on a more global scale. The concept used in this study defines hyperphosphatemia as a “silent killer” due to the effect of the illness on vascular calcification. The sample in the study included the course of the disease in both adults and children. Data collection was carried out by interviewing adults and pediatric neurologists, and the analysis aimed at standard and distinctive features of the course of the disease in adults and children.
The study’s main conclusion is the identification of the fact that an increase in serum phosphorus is directly associated with the mortality of CKD patients. According to Bacchetta et al. (2021), this is a common factor for both adult patients and children.
This study confirms that hyperphosphatemia can delay or prevent chronic kidney disease. It shows that the early detection of hyperphosphatemia is one of the initial dietary and therapeutic approaches that allow preventing the development of severe disabling kidney complications.
References
Bacchetta, J., Bernardor, J., Garnier, C., Naud, C., & Ranchin, B. (2021). Hyperphosphatemia and chronic kidney disease: A major daily concern both in adults and in children. Calcified Tissue International, 108(18), 116-127.